Neurology · COQ8A-Related Ataxia

Monitoring Your Journey: Long-Term Care and Expectations

At a Glance

COQ8A-related ataxia usually progresses slowly, so long-term care focuses on regular neurologic and functional assessments, periodic heart and kidney screening, symptom-triggered seizure evaluation, and continuous CoQ10 treatment to support stability and independence.

Managing COQ8A-related ataxia (ARCA2) is a marathon, not a sprint. Because this condition typically progresses slowly and can involve systems beyond the brain—such as the heart and kidneys—long-term care is built around proactive surveillance. The goal is to detect and treat complications early, before they affect your quality of life ^[1]^[2].

An Example Discussion Checklist for Monitoring

While there is no single international guideline for COQ8A, specialists often use a structured monitoring plan based on research protocols and mitochondrial disease best practices. This is an example checklist to discuss with your treating team ^[3]^[4].

Test / Evaluation	Frequency	Why It Matters
Neurologic Exam (SARA Score)	Every 6 to 12 months ^[3]	Tracks the slow progression of ataxia (approx. 0.45 points/year) and response to treatment ^[5].
Functional Assessments	Every 6 to 12 months ^[3]	Includes timed walking (Timed 25-Foot Walk) and hand coordination (9-Hole Peg Test) ^[3].
Cardiac Screen (Echo/ECG)	Baseline & periodically ^[6]	Screens for cardiomyopathy (heart thickening), which can be life-threatening if undetected ^[6]^[7].
Renal Screen (Urinalysis)	Periodically ^[8]	Checks for proteinuria (protein in urine). If there is concern for renal phosphate wasting, blood phosphate testing plus specific urine assessment is required. Early detection may help stabilize kidney stress ^[8]^[9].
EEG (Brain Wave Test)	Symptom-triggered ^[10]	Used if seizures or “staring spells” are suspected. Routine screening in asymptomatic patients is not standard ^[10]^[11].

Long-Term Progression and Expectations

The natural history of COQ8A-related ataxia is generally described as a slow, progressive coordination loss ^[5].

Rate of Change: In a large cohort of 59 patients, the average progression was estimated at 0.45 points per year on the SARA scale ^[5]. For context, a SARA score ranges from 0 (no ataxia) to 40 (severe ataxia). This is a cohort average, not a personal prediction, and some studies suggest the progression may be even slower in certain patients ^[12]^[13]. The SARA score is just one metric and does not capture cognition, fatigue, or overall quality of life.
The Age of Onset Factor: Generally, a younger age of onset (infancy or early childhood) is associated with more significant symptoms over time ^[14]^[5]. However, this is a population-level observation, and individual experiences vary widely ^[5].
Multisystem Risks: Patients with missense mutations (where a single DNA “letter” is swapped) may have a higher risk of multisystem involvement—affecting the heart, muscles, and brain—compared to those with “loss-of-function” mutations ^[5].

The Impact of Continuous Treatment

The most critical factor in long-term survivorship is the consistent use of high-dose CoQ10 supplementation ^[1].

Stability vs. Improvement: In clinical follow-ups, about half of treated patients show a measurable improvement in their motor skills, while others reach a period of stability where their symptoms stop getting worse ^[5]^[15].
Treatment Interruptions: A small study showed that patients who stopped CoQ10 treatment experienced a faster decline in walking speed compared to those who stayed on the supplement ^[3]. Continuous, lifelong treatment is essential ^[16].
Reversing Complications: Some systemic issues, particularly renal (kidney) manifestations, have been shown in broader primary CoQ10 cohorts to stabilize or even reverse when CoQ10 is started early enough ^[8]^[17].

A Note on Quality of Life

While much of the medical focus is on scores and labs, the ultimate goal of monitoring is to support independence. Regular evaluations allow the care team to adjust physical therapy, school or workplace accommodations, and assistive technologies in real-time ^[18]^[19]. By staying vigilant with screenings, you ensure that manageable complications do not stand in the way of potential.

Common questions in this guide

How often should COQ8A-related ataxia be monitored?

A neurologic exam and functional tests are often scheduled every 6 to 12 months. Heart screening is done at baseline and periodically, kidney testing is periodic, and an EEG, or brain-wave test, is usually ordered when symptoms suggest seizures; your care team should individualize the schedule.

Why do people with COQ8A-related ataxia need heart and kidney screening?

The condition can involve the heart and kidneys even when the main symptoms are neurological. An echocardiogram or ECG can look for cardiomyopathy, while urine testing can find proteinuria or other signs of kidney stress early.

What does a SARA score mean for my outlook?

SARA is a 0-to-40 scale that tracks coordination and ataxia severity; higher scores mean more impairment. Studies report an average change of about 0.45 points per year, but this is a group estimate and does not predict one person’s future or capture fatigue, cognition, or quality of life.

Can CoQ10 improve or stabilize COQ8A-related ataxia?

In follow-up studies, about half of treated patients had measurable motor improvement, while others had a period of stability. Taking prescribed high-dose CoQ10 consistently is important because stopping it has been associated with faster decline in walking speed; do not change treatment without your clinician.

When is an EEG needed for COQ8A-related ataxia?

An EEG, or brain-wave test, is generally considered when seizures or staring spells are suspected. Routine EEG screening is not standard for people without symptoms, so new episodes should be discussed with the treating team.

What does a small rise in my SARA score mean?

A small increase may reflect the slow progression seen in COQ8A-related ataxia and does not by itself prove that CoQ10 is failing. Clinicians usually look at the trend, walking and hand-function tests, symptoms, and treatment consistency before interpreting a change.

Get notified when new evidence is published on Autosomal recessive ataxia due to ubiquinone deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Primary Coenzyme Q10 Deficiency: An Update.
Mantle D, Millichap L, Castro-Marrero J, Hargreaves IP
Antioxidants (Basel, Switzerland) 2023; (12(8)) doi:10.3390/antiox12081652.
PMID: 37627647
2
Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency.
Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, et al.
Kidney international 2022; (102(3)):604-612 doi:10.1016/j.kint.2022.04.029.
PMID: 35643375
3
One-year outcome of coenzyme Q10 supplementation in ADCK3 ataxia (ARCA2).
Schirinzi T, Favetta M, Romano A, et al.
Cerebellum & ataxias 2019; (6()):15 doi:10.1186/s40673-019-0109-2.
PMID: 31890231
4
[An interpretation of the expert consensus on standards for the management of patients with primary mitochondrial disease from the Mitochondrial Medicine Society].
Guo Y, Hong SQ, Jiang L
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2018; (20(11)):887-892.
PMID: 30477617
5
Clinico-Genetic, Imaging and Molecular Delineation of COQ8A-Ataxia: A Multicenter Study of 59 Patients.
Traschütz A, Schirinzi T, Laugwitz L, et al.
Annals of neurology 2020; (88(2)):251-263 doi:10.1002/ana.25751.
PMID: 32337771
6
Primary CoQ10 deficiency with a severe phenotype due to the c.901 C > T (p.R301W) mutation in the COQ8A gene.
Değerliyurt A, Gülleroğlu NB, Kibar Gül AE
The International journal of neuroscience 2024; (134(2)):148-152 doi:10.1080/00207454.2022.2095269.
PMID: 35757998
7
Mitochondrial Cardiomyopathies.
El-Hattab AW, Scaglia F
Frontiers in cardiovascular medicine 2016; (3()):25 doi:10.3389/fcvm.2016.00025.
PMID: 27504452
8
Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q10 Biosynthesis Disorders.
Wahedi A, Sudhakar S, Lam A, et al.
Neurology. Genetics 2024; (10(6)):e200209 doi:10.1212/NXG.0000000000200209.
PMID: 39601013
9
Autosomal Recessive Spinocerebellar Ataxia Type 9 With a Response to Phosphate Repletion: A Case Report.
Haji S, Miyamoto R, Morino H, et al.
Neurology. Genetics 2023; (9(3)):e200070 doi:10.1212/NXG.0000000000200070.
PMID: 37529414
10
Adult-onset status epilepticus in patients with COQ8A coenzyme Q10 deficiency: A case series.
Tsalouchidou PE, Juenemann C, Hahn W, et al.
Epilepsy & behavior reports 2024; (28()):100716 doi:10.1016/j.ebr.2024.100716.
PMID: 39712550
11
A characteristic occipital epileptiform EEG pattern in ADCK3-related mitochondrial disease.
Arntsen V, Sand T, Hikmat O, et al.
Epileptic disorders : international epilepsy journal with videotape 2021; (23(2)):281-290 doi:10.1684/epd.2021.1269.
PMID: 33881396
12
Longitudinal Analysis of Natural History Progression of Rare and Ultra-Rare Cerebellar Ataxias Using Item Response Theory.
Hamdan A, Hendrickx N, Hooker AC, et al.
Clinical pharmacology and therapeutics 2024; (116(6)):1593-1605 doi:10.1002/cpt.3466.
PMID: 39403821
13
Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients.
Traschütz A, Adarmes-Gómez AD, Anheim M, et al.
Annals of neurology 2023; (94(3)):470-485 doi:10.1002/ana.26712.
PMID: 37243847
14
Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review.
Galosi S, Barca E, Carrozzo R, et al.
Parkinsonism & related disorders 2019; (68()):8-16 doi:10.1016/j.parkreldis.2019.09.015.
PMID: 31621627
15
Coenzyme Q10 Supplementation in a Child with Biallelic COQ8A Variants: A Case Report.
Motoi H, Watanabe R, Shirai A, et al.
Case reports in neurology 2026; (18(1)):121-127 doi:10.1159/000550495.
PMID: 41769026
16
The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review.
Wang Y, Hekimi S
Journal of cellular and molecular medicine 2022; (26(17)):4635-4644 doi:10.1111/jcmm.17488.
PMID: 35985679
17
Mitochondrial Disease and the Kidney With a Special Focus on CoQ10 Deficiency.
Schijvens AM, van de Kar NC, Bootsma-Robroeks CM, et al.
Kidney international reports 2020; (5(12)):2146-2159 doi:10.1016/j.ekir.2020.09.044.
PMID: 33305107
18
Identification of International Classification of Functioning, Disability and Health categories in a multifaceted rehabilitation program for degenerative cerebellar ataxia: a descriptive analysis of real-world clinical practice.
Hiramatsu Y, Fujimoto H, Otomune H, et al.
Disability and rehabilitation 2026; (48(21)):6961-6979 doi:10.1080/09638288.2026.2646108.
PMID: 41904646
19
Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements.
Mancuso M, Bellusci M, Carelli V, et al.
European journal of neurology 2026; (33(4)):e70588 doi:10.1111/ene.70588.
PMID: 41999163

This page explains long-term monitoring for COQ8A-related ataxia for informational purposes only and does not constitute medical advice. Your neurology team should tailor screening, CoQ10 treatment, and supportive care to your needs.